The multi-year strategic partnership is intended to support commercial demand of Viking Therapeutics’ GLP-1 candidate, VK2735.

The transaction includes Unloxcyt (cosibelimab-ipdl), which was approved by FDA in December 2024 for treatment of adults with cutaneous squamous cell carcinoma (cSCC).

Rivaroxaban, long known under the brand name Xarelto, is an anticoagulant, a classification that is among the most-prescribed medications in the United States.

In an interview with Pharmaceutical Technology®, Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.

The company’s 100,000-sq.-ft. space is expected to enhance its capabilities for commercial oral dose treatment manufacturing in a variety of therapeutic areas.

Sterimove will make its North American debut at the April 1–3, 2025 event.

Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments, in an interview with Pharmaceutical Technology®.

The investment is intended for the Halo Pharma facility in Whippany, NJ, and aims to help relieve capacity shortages in the injectable supply chain in the United States.

Pharmaceutical Technology® chats with Miguel Forte from ISCT and Kiji Therapeutics about expectations for 2025 and the future technology agenda for industry.

Gender diversity and equality in leadership positions have been shown to improve profitability and return on equity through greater innovation and more creative solutions.

In an interview with Pharmaceutical Technology®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.

The €4 million (US$4.3 million) project is current good manufacturing practice compliant, and includes an accompanying cartoning machine.

The detector features specialized, solid-state dual infrared (IR) sources and dual IR receivers which provide continual cross-checks and internal adjustments to adhere to factory calibration.

The alterations are the result of an agency review of findings from a clinical trial, and data from required postmarket studies.

In an interview with Pharmaceutical Technology®, Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the M&A landscape from 2024 and his expectations of what is to come next.

The company said this blender supports applications for which either stainless steel or carbon steel may not be suitable.

In an interview with Pharmaceutical Technology®, Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.

The company first announced its intention to build the state-of-the-art facility as part of a €900 million investment in July 2024.

Brian Feth, Xcell Biosciences; Thomas Heathman, Ori Biotech; and Matthew Lauber, Waters Corporation go behind the headlines and discuss commercialization challenges in the cell and gene therapy space; advances in new genomics tools from Roche, Illumina, and Eikon; and the latest development and manufacturing partnerships.

Pharmaceutical Technology® discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer with Mike Baird from Schlafender Hase.

The Biotech and Biomanufacturing Hub will help European companies access funding, navigate regulations, and speed up market access.

The company now performs product-sterility testing through rapid microbiological methods at two laboratory sites in the United States and one in Germany.

Xiao-Yan Cai, PhD, shares insights into her leadership style, the importance of motivation in the workplace, and how she balances repetition with innovation, discussing how hobbies and resilience uniquely shape her professional approach, emphasizing the value of perseverance and preparation in both science and life.

CHMP gave its opinion and a recommendation for marketing authorization to Fabhalta (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway.

Compliance and competitiveness are key factors in aseptic processing, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.

Artificial intelligence, among other technological advances, is pushing innovation boundaries.

Jaypirca (pirtobrutinib) has received a conditional marketing authorization from EMA for mantle cell lymphoma. The drug was approved in the United States in 2023 for several indications.

More than 6000 rare diseases—those which affect fewer than one in 2000 people each—are acknowledged in the medical community, with 72% of them being genetic.